Pink SheetWhere talk of regulatory flexibility is common in contested approval decisions, the US Food and Drug Administration’s Psychopharmacology Drugs Advisory Committee emphasized maintaining high and rigoro
Pink SheetOtsuka and H. Lundbeck ’s post hoc bid to elevate a hypothesis-generating Phase II study into a supporting evidentiary role will be a focus of the FDA’s Psychopharmacology Drugs Advisory Committee r
ScripLundbeck’s transformation under CEO Charl van Zyl continues apace and the CNS-focused Danish drugmaker has raised its full-year guidance after posting a strong set of financials for the first quarter.
In VivoAmid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy